

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia, 22313-1450 on the date shown below.

Dated: May 19, 2003      Signature: *Sharon M. Sinton*  
(Sharon M. Sinton)

#20

Docket No.: 01017/36917A  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Medlock et al.

Application No.: 09/810,927

Group Art Unit: 1646

Filed: March 16, 2001

Examiner: J. Anders

For: IL-17 RECEPTOR LIKE MOLECULES AND  
USES THEREOF

**PETITION FOR ACCEPTANCE OF COLOR PHOTOGRAPH DRAWINGS  
PURSUANT TO 37 C.F.R. §§ 1.84(a)(2), AND 1.84(b)(2)**

Commissioner for Patents  
Alexandria, VA 22313

Sir:

Pursuant to 37 C.F.R. §§ 1.84(a)(2) and 1.84(b)(2), Applicants respectfully request to have color photograph drawings accepted in the above-identified utility patent application (hereafter "the application").

Color drawings may be considered necessary for Figs. 10A-10H and 11A-11J because, in the application, these figures are described as depicting H & E staining, B220 staining, and F4/80 staining, which are color stains for identifying various immunological cells in tissue samples (*see* specification, page 165, lines 4-22). The various colored distinctions appear as different shades of black/grey when the figures are reproduced in black and white, rather than as the colors characteristic of H & E staining, B220 staining, or F4/80 staining. The various colored distinctions not only identify particular immunological cells but also the biological state of these cells (i.e. myeloid hyperplasia) (page 165, lines 18-22). Thus, color figures may be considered necessary in this application even though one skilled in the art is capable of understanding the staining depicted in Figures 10A-10H and 11A-11J by reference to black and white copies of these figures.

Color drawings may be considered necessary for Figures 17 and 18 because, in the application, these figures are described as 2-color flow cytometric dot plots. These 2-color flow cytometric dot plots depict the change in immunologic cell populations (granulocytes, eosinophils) in the IL-17 like transgenic mice vs. their non-transgenic littermate controls using either CD45R+ and IL-17 like-Fc (Figure 17) or CD4 and IL-17 like-Fc (Figure 18) markers to label the immunologic cells (*see* specification at page 19, line 30 to page 20, line 28). Each particular immunologic cell that is labeled appears as a particular color on the dot plot. The various colored distinctions of each cell population appear as non-distinctive black dots when the figures are produced in black and white (see transgenic panel B in Figures 17 and 18).

Pursuant to 37 C.F.R. §§ 1.84(a)(2)(i) and 1.17(h), a check for \$130.00 is enclosed herewith.

Pursuant to 37 C.F.R. § 1.84(a)(2)(ii), three sets of color drawings of Figures 10, 11, 17, 18 and 21 accompany this petition.


Pursuant to 37 C.F.R. §§ 1.84(a)(2)(iii) and 1.312, a proposed amendment is submitted herewith to insert the following language in the specification:

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

This petition is not intended as an admission that color drawings are necessary to comply with any statutory requirement.

Dated: May 19, 2003

Respectfully submitted,

By   
Sharon M. Sintich

Registration No.: 48,484  
MARSHALL, GERSTEIN & BORUN  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Agents for Applicant